X0609 4 2026-08-03 0 0001649094 Vaxcyte, Inc. PCVX 0001230724 GUGGENHIME ANDREW false C/O VAXCYTE, INC. 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070 0 1 0 0 PRESIDENT AND CFO 1 Common Stock 2026-08-03 4 M 0 10000 5.35 A 115176 D Common Stock 2026-08-03 4 S 0 6956 53.761 D 108220 D Common Stock 2026-08-03 4 S 0 3044 54.178 D 105176 D Common Stock 61850 I See Footnote Stock Option (right to buy) 5.35 2026-08-03 4 M 0 10000 0 D 2030-05-11 Common Stock 10000 216827 D Includes 781 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026. The price reported is a weighted-average price. The shares were sold at prices ranging from $53.06 to $54.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $54.07 to $54.44. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee. Option is fully vested and exercisable. Andrew Guggenhime, by /s/ Peter N. Efremenko, Attorney-In-Fact 2026-08-05